Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,743 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.
Fukushima R, Kobayashi Y, Fukuhara S, Miyamoto K, Munakata W, Maruyama D, Kim SW, Watanabe T, Taniguchi H, Maeshima A, Tobinai K. Fukushima R, et al. Among authors: kim sw. J Chemother. 2016 Apr;28(2):116-22. doi: 10.1080/1120009X.2015.1110898. Epub 2016 Apr 19. J Chemother. 2016. PMID: 27093518
Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.
Tada K, Maeshima AM, Hiraoka N, Yamauchi N, Maruyama D, Kim SW, Watanabe T, Katayama N, Heike Y, Tobinai K, Kobayashi Y. Tada K, et al. Among authors: kim sw. Cancer Immunol Immunother. 2016 Oct;65(10):1213-22. doi: 10.1007/s00262-016-1883-9. Epub 2016 Aug 13. Cancer Immunol Immunother. 2016. PMID: 27522583 Free PMC article.
Double-Expressor Lymphoma Is Associated with Poor Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Kawashima I, Inamoto Y, Maeshima AM, Nomoto J, Tajima K, Honda T, Shichijo T, Kawajiri A, Takemura T, Onishi A, Ito A, Tanaka T, Fuji S, Kurosawa S, Kim SW, Maruyama D, Tobinai K, Kobayashi Y, Fukuda T. Kawashima I, et al. Among authors: kim sw. Biol Blood Marrow Transplant. 2018 Feb;24(2):294-300. doi: 10.1016/j.bbmt.2017.10.013. Epub 2017 Oct 14. Biol Blood Marrow Transplant. 2018. PMID: 29037890 Free article.
Successful full-dose DeVIC therapy in a patient with advanced-stage extranodal natural killer/T-cell lymphoma refractory to L-asparaginase.
Watanabe J, Makita S, Ito Y, Hatta S, Suzuki T, Yuda S, Maeshima AM, Fukuhara S, Munakata W, Suzuki T, Maruyama D, Kim SW, Izutsu K. Watanabe J, et al. Among authors: kim sw. Ann Hematol. 2018 Sep;97(9):1739-1740. doi: 10.1007/s00277-018-3335-4. Epub 2018 Apr 16. Ann Hematol. 2018. PMID: 29663028 No abstract available.
Association of CD204+ macrophages with poor outcomes of malignant lymphomas not in remission treated by allogeneic HCT.
Kawajiri A, Kitano S, Maeshima AM, Inamoto Y, Tajima K, Takemura T, Tanaka T, Ito A, Okinaka K, Kurosawa S, Kim SW, Taniguchi H, Ogawa C, Izutsu K, Yamamoto N, Fukuda T. Kawajiri A, et al. Among authors: kim sw. Eur J Haematol. 2019 Dec;103(6):578-587. doi: 10.1111/ejh.13324. Epub 2019 Oct 8. Eur J Haematol. 2019. PMID: 31487403 Clinical Trial.
Alectinib, an anaplastic lymphoma kinase (ALK) inhibitor, as a bridge to allogeneic stem cell transplantation in a patient with ALK-positive anaplastic large-cell lymphoma refractory to chemotherapy and brentuximab vedotin.
Nakai R, Fukuhara S, Maeshima AM, Kim SW, Ito Y, Hatta S, Suzuki T, Yuda S, Makita S, Munakata W, Suzuki T, Maruyama D, Izutsu K. Nakai R, et al. Among authors: kim sw. Clin Case Rep. 2019 Nov 15;7(12):2500-2504. doi: 10.1002/ccr3.2543. eCollection 2019 Dec. Clin Case Rep. 2019. PMID: 31893088 Free PMC article.
9,743 results